AstraZeneca reportedly made the $10 billion bid in October. It would pay $124 per share for Rhythm, which specializes in treatments for metabolic diseases and severe obesity.
Since the bid was announced, Rhythm's share price rose 28 percent on Wednesday to just under $111.
A purchase would expand AstraZeneca's portfolio of treatments for rare diseases.
What do you think?